Search

Your search keyword '"Ross, Jeffrey"' showing total 4,474 results
Start Over Author "Ross, Jeffrey"
4,474 results on '"Ross, Jeffrey"'

1. Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study

Author

Basin, Michael F., Miguel, Carla M., Jacob, Joseph M., Goldberg, Hanan, Grivas, Petros, Spiess, Philippe E., Necchi, Andrea, Kamat, Ashish M., Pavlick, Dean C., Huang, Richard S. P., Lin, Douglas I., Danziger, Natalie, Sokol, Ethan S., Sivakumar, Smruthy, Graf, Ryon, Cheng, Liang, Vasan, Neil, Ross, Jeffrey, Basnet, Alina, and Bratslavsky, Gennady

Published
2024
Full Text
View/download PDF

2. Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Author

Bhave, Manali A., Quintanilha, Julia C. F., Tukachinsky, Hanna, Li, Gerald, Scott, Takara, Ross, Jeffrey S., Pasquina, Lincoln, Huang, Richard S. P., McArthur, Heather, Levy, Mia A., Graf, Ryon P., and Kalinsky, Kevin

Published
2024
Full Text
View/download PDF

5. Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab

Author

Lin, Douglas I., Quintanilha, Julia C. F., Danziger, Natalie, Lang, Lixin, Levitan, Diane, Hayne, Cynthia, Hiemenz, Matthew C., Smith, David L., Albacker, Lee A., Leibowitz, Jeffrey, Mata, Douglas A., Decker, Brennan, Lakis, Sotirios, Patel, Nimesh R., Graf, Ryon P., Elvin, Julia A., Ross, Jeffrey S., Pattani, Varun, Huang, Richard S. P., and Wehn, Amy K.

Published
2024
Full Text
View/download PDF

7. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs

Author

Williams, Erik A, Ravindranathan, Ajay, Gupta, Rohit, Stevers, Nicholas O, Suwala, Abigail K, Hong, Chibo, Kim, Somang, Yuan, Jimmy Bo, Wu, Jasper, Barreto, Jairo, Lucas, Calixto-Hope G, Chan, Emily, Pekmezci, Melike, LeBoit, Philip E, Mully, Thaddeus, Perry, Arie, Bollen, Andrew, Van Ziffle, Jessica, Devine, W Patrick, Reddy, Alyssa T, Gupta, Nalin, Basnet, Kristen M, Macaulay, Robert JB, Malafronte, Patrick, Lee, Han, Yong, William H, Williams, Kevin Jon, Juratli, Tareq A, Mata, Douglas A, Huang, Richard SP, Hiemenz, Matthew C, Pavlick, Dean C, Frampton, Garrett M, Janovitz, Tyler, Ross, Jeffrey S, Chang, Susan M, Berger, Mitchel S, Jacques, Line, Song, Jun S, Costello, Joseph F, and Solomon, David A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Neurofibromatosis, Cancer Genomics, Genetics, Pediatric, Rare Diseases, Human Genome, Neurosciences, Biotechnology, 2.1 Biological and endogenous factors, Humans, INDEL Mutation, Transcriptional Activation, Neurilemmoma, Neuroma, Acoustic, Mutation, Nerve Sheath Neoplasms, SOXE Transcription Factors, myelination, PMP2, Schwann cell, schwannoma, SOX10, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundSchwannomas are common peripheral nerve sheath tumors that can cause severe morbidity given their stereotypic intracranial and paraspinal locations. Similar to many solid tumors, schwannomas and other nerve sheath tumors are primarily thought to arise due to aberrant hyperactivation of the RAS growth factor signaling pathway. Here, we sought to further define the molecular pathogenesis of schwannomas.MethodsWe performed comprehensive genomic profiling on a cohort of 96 human schwannomas, as well as DNA methylation profiling on a subset. Functional studies including RNA sequencing, chromatin immunoprecipitation-DNA sequencing, electrophoretic mobility shift assay, and luciferase reporter assays were performed in a fetal glial cell model following transduction with wildtype and tumor-derived mutant isoforms of SOX10.ResultsWe identified that nearly one-third of sporadic schwannomas lack alterations in known nerve sheath tumor genes and instead harbor novel recurrent in-frame insertion/deletion mutations in SOX10, which encodes a transcription factor responsible for controlling Schwann cell differentiation and myelination. SOX10 indel mutations were highly enriched in schwannomas arising from nonvestibular cranial nerves (eg facial, trigeminal, vagus) and were absent from vestibular nerve schwannomas driven by NF2 mutation. Functional studies revealed these SOX10 indel mutations have retained DNA binding capacity but impaired transactivation of glial differentiation and myelination gene programs.ConclusionsWe thus speculate that SOX10 indel mutations drive a unique subtype of schwannomas by impeding proper differentiation of immature Schwann cells.

Published
2023

12. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

Author

Mercinelli, Chiara, Moschini, Marco, Cigliola, Antonio, Mattorre, Benedetta, Tateo, Valentina, Basile, Giuseppe, Cogrossi, Laura L., Maiorano, Brigida A., Patanè, Damiano A., Raggi, Daniele, Pastorino, Giovanni L., Re, Chiara, Colecchia, Maurizio, Lucianò, Roberta, Colombo, Renzo, Brembilla, Giorgio, De Cobelli, Francesco, Briganti, Alberto, Pavlick, Dean C., Ross, Jeffrey S., Montorsi, Francesco, Bellone, Matteo, and Necchi, Andrea

Published
2024
Full Text
View/download PDF

13. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer

Author

Hill, Breana L, Graf, Ryon P, Shah, Kunal, Danziger, Natalie, Lin, Douglas I, Quintanilha, Julia, Li, Gerald, Haberberger, James, Ross, Jeffrey S, Santin, Alessandro D, Slomovitz, Brian, Elvin, Julia A, and Eskander, Ramez N

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, Digestive Diseases, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Female, Humans, Biomarkers, Tumor, Colorectal Neoplasms, DNA Mismatch Repair, Endometrial Neoplasms, High-Throughput Nucleotide Sequencing, Immune Checkpoint Inhibitors, Microsatellite Instability, endometrium, uterine cancer, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectiveMolecular profiling is developing to inform treatment in endometrial cancer. Using real world evidence, we sought to evaluate frontline immune checkpoint inhibitor vs chemotherapy effectiveness in advanced endometrial cancer, stratified by Tumor Mutational Burden (TMB) ≥10 mut/MB and microsatellite instability (MSI).MethodsPatients with advanced endometrial cancer in the US-based de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database were included. Data originated from patients treated between January 2011- March 2022 at 280 US clinics. Next-generation sequencing assays were performed via FoundationOne or FoundationOneCDx. Longitudinal clinical data were derived from electronic health records. Immune checkpoint inhibitor treatment included pembrolizumab, dostarlimab, and nivolumab monotherapies. Time to next treatment, time to treatment discontinuation, and overall survival were assessed with the log-rank test and Cox proportional hazard models with adjusted hazard ratios (aHR) for known prognostic factors. We used the Likelihood ratio test to compare biomarker performance.ResultsA total of 343 patients received chemotherapy and 28 received immune checkpoint inhibitor monotherapy as frontline treatment. Patients who received monotherapy were more likely to be stage III at diagnosis (immune checkpoint inhibitor: 54.6% vs chemotherapy: 15.0%; p

Published
2023

20. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.

Author

Lee, Jessica, Sivakumar, Smruthy, Schrock, Alexa, Madison, Russell, Fabrizio, David, Gjoerup, Ole, Ross, Jeffrey, Frampton, Garrett, Napalkov, Pavel, Montesion, Meagan, Schutzman, Jennifer, Ye, Xin, Hegde, Priti, Nagasaka, Misako, Oxnard, Geoffrey, Sokol, Ethan, Ou, Sai-Hong, and Shi, Zhen

Abstract

Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered samples from 426,706 adult patients with solid or hematologic malignancies using comprehensive genomic profiling; additional analyses included 62,369 liquid biopsy and 7241 pediatric samples. 23% of adult pan-cancer samples had KRAS alterations; 88% were mutations, most commonly G12D/G12V/G12C/G13D/G12R, and prevalence was similar in liquid biopsies. Co-alteration landscapes were largely similar across KRAS mutations but distinct from KRAS wild-type, though differences were observed in some tumor types for tumor mutational burden, PD-L1 expression, microsatellite instability, and other mutational signatures. Prognosis of KRAS-mutant versus other genomic cohorts of lung, pancreatic, and colorectal cancer were assessed using a real-world clinicogenomic database. As specific KRAS inhibitors and combination therapeutic strategies are being developed, genomic profiling to understand co-alterations and other biomarkers that may modulate response to targeted or immunotherapies will be imperative.

Published
2022

22. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

Author

Li, Roger, Hensley, Patrick J., Gupta, Shilpa, Al-Ahmadie, Hikmat, Babjuk, Marko, Black, Peter C., Brausi, Maurizio, Bree, Kelly K., Fernández, Mario I., Guo, Charles C., Horowitz, Amir, Lamm, Donald L., Lerner, Seth P., Lotan, Yair, Mariappan, Paramananthan, McConkey, David, Mertens, Laura S., Mir, Carmen, Ross, Jeffrey S., O’Donnell, Michael, Palou, Joan, Pohar, Kamal, Steinberg, Gary, Soloway, Mark, Spiess, Philippe E., Svatek, Robert S., Tan, Wei Shen, Taoka, Rikiya, Buckley, Roger, and Kamat, Ashish M.

Published
2024
Full Text
View/download PDF

25. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Author

Krämer, Alwin, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai-Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A, Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S, Moch, Holger, and Mileshkin, Linda

Published
2024
Full Text
View/download PDF

28. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma

Author

Williams, Erik A., Vegas, Isabella, El-Senduny, Fardous F., Zhang, Jessica, Mata, Douglas A., Hiemenz, Matthew C., Hughes, Sarah R., Sa, Brianna C., Kraft, Garrett P., Gorbatov, Nicole, Foley-Peres, Kathleen, Sanchez, Edward Z., Milikowski, Clara, Williams, Kevin Jon, Ross, Jeffrey S., Kurzrock, Razelle, Montgomery, Elizabeth A., Lombard, David B., and Kumar, Surinder

Published
2024
Full Text
View/download PDF

29. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Author

Gounder, Mrinal M, Agaram, Narasimhan P, Trabucco, Sally E, Robinson, Victoria, Ferraro, Richard A, Millis, Sherri Z, Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P D’, Dickson, Mark A, Keohan, Mary Lou, Kelly, Ciara M, Agulnik, Mark, Chawla, Sant P, Choy, Edwin, Chugh, Rashmi, Meyer, Christian F, Myer, Parvathi A, Moore, Jessica L, Okimoto, Ross A, Pollock, Raphael E, Ravi, Vinod, Singh, Arun S, Somaiah, Neeta, Wagner, Andrew J, Healey, John H, Frampton, Garrett M, Venstrom, Jeffrey M, Ross, Jeffrey S, Ladanyi, Marc, Singer, Samuel, Brennan, Murray F, Schwartz, Gary K, Lazar, Alexander J, Thomas, David M, Maki, Robert G, Tap, William D, Ali, Siraj M, and Jin, Dexter X

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Clinical Research, Human Genome, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Bone Neoplasms, Genomics, Humans, Mutation, Osteosarcoma, Prospective Studies, Sarcoma
Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (

Published
2022

30. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

Author

Posada, Jessica M., Yakirevich, Evgeny, Kamat, Ashish M., Sood, Akshay, Jacob, Joseph M., Bratslavsky, Gennady, Grivas, Petros, Spiess, Philippe E., Li, Roger, Necchi, Andrea, Mega, Anthony E., Golijanin, Dragan J., Pavlick, Dean, Huang, Richard S.P., Lin, Douglas, Danziger, Natalie, Sokol, Ethan S., Sivakumar, Smruthy, Ross, Jeffrey S., and Cheng, Liang

Published
2024
Full Text
View/download PDF

35. FGFR Inhibition in Urothelial Carcinoma

Author

Li, Roger, Linscott, Joshua, Catto, James W.F., Daneshmand, Siamak, Faltas, Bishoy M., Kamat, Ashish M., Meeks, Joshua J., Necchi, Andrea, Pradere, Benjamin, Ross, Jeffrey S., van der Heijden, Michiel S., van Rhijn, Bas W.G., and Loriot, Yohann

Published
2024
Full Text
View/download PDF

36. Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype

Author

Wang, Jake X., Harikumar, Vishnu, Downing, Malia B., Aasi, Sumaira Z., Aung, Phyu P., Barker, Christopher A., Bolotin, Diana, Bordeaux, Jeremy S., Cartee, Todd V., Chandra, Sunandana, Cho, Nancy L., Choi, Jennifer N., Chung, Kee Yang, Cliby, William A., Dorigo, Oliver, Eisen, Daniel B., Fujisawa, Yasuhiro, Golda, Nicholas, Halfdanarson, Thorvardur R., Iavazzo, Christos, Brian Jiang, Shang I., John, Esther M., Kanitakis, Jean, Keimig, Emily L., Khan, Ashraf, Linos, Eleni, Kim, John Y.S., Kuzel, Timothy M., Lawrence, Naomi, Leitao, Mario M., Jr., MacLean, Allan B., Maher, Ian A., Mittal, Bharat B., Nehal, Kishwer S., Ozog, David M., Pettaway, Curtis A., Rajan, Neil, Ross, Jeffrey S., Rossi, Anthony M., Servaes, Sabah, Solomon, Michael J., Thomas, Valencia D., Tolia, Maria, Voelzke, Bryan B., Waldman, Abigail, Wong, Michael K., Zhou, Youwen, Brackett, Alexandria, Poon, Emily, Ahmed, Areeba, Kibbi, Nour, Owen, Joshua L., Worley, Brandon, and Alam, Murad

Published
2024
Full Text
View/download PDF

37. Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer

Author

Mata, Douglas A., Harries, Lukas, Williams, Erik A., Hiemenz, Matthew C., Decker, Brennan, Tse, Julie Y., Janovitz, Tyler, Ferguson, Donna C., Speece, Iain A., Margolis, Matthew L., Mathews, Benjamin, Fedorchak, Kyle, Killian, J. Keith, Xiao, Jinpeng, Tolba, Khaled A., Ramkissoon, Shakti, Vergilio, Jo-Anne, Elvin, Julia A., Oxnard, Geoffrey R., Ross, Jeffrey S., and Huang, Richard S.P.

Subjects
Nucleotide sequencing -- Methods, DNA sequencing -- Methods, Lung cancer -- Diagnosis -- Genetic aspects, Molecular diagnostic techniques -- Methods, Health
Abstract

Context.--Multiple procedural techniques can be used to obtain tissue to create a formalin-fixed, paraffin-embedded specimen for comprehensive genomic profiling (CGP) in lung cancer. The literature is mixed on whether the procedure affects CGP success. Objective.--To examine whether biopsy procedure affects lung cancer CGP success. Design.--This was a cross-sectional study of all patients with lung cancer whose specimens were submitted for CGP between January and February 2020. Multiple quality control metrics were used to determine whether cases were successfully profiled. Results.--In all, 3312 samples were identified. Overall, 67.5% (2236 of 3312) of samples were obtained from biopsies, 13.0% (432 of 3312) from fine-needle aspirations (FNAs), 9.7% (321 of 3312) from resections, 5.3% (174 of 3312) from fluid cytology cell blocks, and 4.5% (149 of 3312) from bone biopsies. Overall, 70.1% (2321 of 3312) of cases passed CGP, 15.4% (510 of 3312) of cases were released as qualified reports, and 14.5% (481 of 3312) of cases failed CGP. Resection samples were the most likely to be successfully sequenced, failing in only 2.8% (9 of 321) of instances, while fluid cytology specimens were the least likely, failing in 23.0% (40 of 174) of instances. Biopsy (14.5% [324 of 2236]), FNA (18.5% [80 of 432]), and bone biopsy (18.8% [28 of 149]) specimens failed at intermediate frequencies. On multivariate logistic regression analysis of CGP success on specimen type, fluid cytology (odds ratio [OR], 0.08; 95% CI, 0.03-0.19), biopsy (OR, 0.25; 95% CI, 0.11-0.52), FNA (OR, 0.14; 95% CI, 0.06-0.32), and bone biopsy (OR, 0.07; 95% CI, 0.03-0.17) specimens had decreased odds of CGP success relative to resection samples. Among patients with successfully sequenced samples, 48.0% were eligible for at least 1 therapy, based on a companion diagnostic or National Comprehensive Cancer Network biomarker. Conclusions.--The method of tissue acquisition was an important preanalytic factor that determined whether a sample would be successfully sequenced and whether a clinically actionable genomic alteration would be detected. doi: 10.5858/arpa.2021-0313-OA, In 2020, lung cancer was the tumor type with the highest mortality, with 1.8 million deaths worldwide. (1) The most common type of lung cancer is non-small cell lung carcinoma [...]

Published
2023
Full Text
View/download PDF

40. Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.

Author

Jardim, Denis L, Millis, Sherri Z, Ross, Jeffrey S, Woo, Michelle Sue-Ann, Ali, Siraj M, and Kurzrock, Razelle

Subjects
Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. Herein, we analyzed prostate cancer samples (majority metastatic) using comprehensive genomic profiling performed by next-generation sequencing (315 genes, >500× coverage) for alterations in activating and sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A [loss], SMARCB1), androgen receptor (AR) gene, and coalterations in genes leading to cyclin inhibitor therapeutic resistance (RB1 and CCNE1). Overall, cyclin sensitizing pathway genomic abnormalities were found in 9.7% of the 5,356 tumors. Frequent alterations included CCND1 amplification (4.2%) and CDKN2A and B loss (2.4% each). Alterations in possible resistance genes, RB1 and CCNE1, were detected in 9.7% (up to 54.6% in neuroendocrine) and 1.2% of cases, respectively, whereas AR alterations were seen in 20.9% of tumors (~27.3% in anaplastic). Cyclin sensitizing alterations were also more frequently associated with concomitant AR alterations.

Published
2021

42. Recurrent secondary genomic alterations in desmoplastic small round cell tumors

Author

Chow, Warren A, Yee, Jiing-Kuan, Tsark, Walter, Wu, Xiwei, Qin, Hanjun, Guan, Min, Ross, Jeffrey S, Ali, Siraj M, and Millis, Sherri Z

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Rare Diseases, Clinical Research, Cancer, Pediatric, Orphan Drug, Biotechnology, Human Genome, Pediatric Cancer, Cancer Genomics, 2.1 Biological and endogenous factors, Adolescent, Adult, Aged, Biomarkers, Tumor, Child, Chromosome Aberrations, DNA-Binding Proteins, Desmoplastic Small Round Cell Tumor, Female, Genome, Human, Humans, Male, Middle Aged, MutS Homolog 3 Protein, Neoplasm Recurrence, Local, Oncogene Proteins, Fusion, Prognosis, RNA-Binding Protein EWS, Receptor, Fibroblast Growth Factor, Type 4, Transcription Factors, Translocation, Genetic, Tumor Suppressor Protein p53, WT1 Proteins, Young Adult, Desmoplastic small round cell tumor, Sarcoma, Genomic profiling, FGFR4, Clinical Sciences, Genetics & Heredity, Clinical sciences
Abstract

BackgroundDesmoplastic small round cell tumor (DSRCT) is a rare, highly aggressive, translocation-associated soft-tissue sarcoma that primarily affects children, adolescents, and young adults, with a striking male predominance. It is characterized by t(11;22) generating a novel EWSR1-WT1 fusion gene. Secondary genomic alterations are rarely described.MethodsTumor tissue from 83 DSRCT patients was assayed by hybrid-capture based comprehensive genomic profiling, FoundationOne® Heme next generation sequencing analysis of 406 genes and RNA sequencing of 265 genes. Tumor mutation burden was calculated from a minimum of 1.4 Mb sequenced DNA. Microsatellite instability status was determined by a novel algorithm analyzing 114 specific loci.ResultsComprehensive genomic profiling identified several genomically-defined DSRCT subgroups. Recurrent genomic alterations were most frequently detected in FGFR4, ARID1A, TP53, MSH3, and MLL3 genes. With the exception of FGFR4, where the genomic alterations predicted activation, most of the alterations in the remaining genes predicted gene inactivation. No DSRCT were TMB or MSI high.ConclusionsIn summary, recurrent secondary somatic alterations in FGFR4, ARID1A, TP53, MSH3, and MLL3 were detected in 82% of DSRCT, which is significantly greater than previously reported. These alterations may have both prognostic and therapeutic implications.

Published
2020

43. From Fledgling Network to the Creation of an Official Division of the American Society of Criminology: The Growth of Convict Criminology 2.0

Author

Ross, Jeffrey Ian and Tietjen, Grant

Subjects
Trade and professional associations, International relations, Law
Abstract

Over the last decade, the Convict Criminology (CC) network has gone through a handful of significant changes. These developments culminated in the establishment of the official Division of Convict Criminology [...]

Published
2022

44. Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma

Author

Margolis, Matthew, Janovitz, Tyler, Laird, Jason, Mata, Douglas A., Montesion, Meagan, Lee, Jessica K., Madison, Russell W., Schrock, Alexa B., Tukachinsky, Hanna, Allen, Justin M., Erlich, Rachel, Hiemenz, Matthew C., Huang, Richard S. P., Elvin, Julia, Vergilio, Jo-Anne, Lin, Douglas I., Ross, Jeffrey, Oxnard, Geoffrey, and Decker, Brennan

Published
2022
Full Text
View/download PDF

46. Teaching about Graffiti and Street Art to Undergraduate Students at U.S. Universities: Confronting Challenges and Seizing Opportunities

Author

Ross, Jeffrey Ian and Lennon, John F.

Abstract

This paper reviews two scholars' experiences teaching about the subjects of graffiti and street art to undergraduate students in U.S. universities. Using auto-ethnographical methods, the instructors review the challenges that they encountered and the various strategies they experimented with to overcome these difficulties. Issues discussed include the unique composition of the student body, the methods by which the students were introduced to the subject matter, choice of readings, assignments, and evaluation procedures. The authors progress from a slow and perhaps cautious introduction of the material on graffiti and street art into existing classes, to a full-fledged course on the subject matter. Suggestions are presented for other instructors considering teaching a class or assignments on the subject matter of graffiti and street art.

Published
2018

48. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Author

Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., and Jonkers, Jos

Published
2022
Full Text
View/download PDF

49. Ewing-Sarkom

Author

Moore, Kevin R., primary, Ross, Jeffrey S., additional, and Thieme, Stefan Felix, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results